Green Ridge Wealth Planning’s Actuate Therapeutics ACTU Stock Holding History

Green Ridge Wealth Planning’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.8K	Hold	10,000	–	–	﹤0.01%	88
2026 Q2	$15.3K	Buy	+10,000	New	+$23.2K	0.01%	94

Other funds holding ACTU

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Green Ridge Wealth Planning's ACTU Position: Q3 2026 in Review

Green Ridge Wealth Planning held its Actuate Therapeutics (ACTU) position steady in Q3 2026 at 10,000 shares worth $7.8K. The position accounts for ﹤0.01% of the portfolio, ranked #88.

Green Ridge Wealth Planning first reported a position in ACTU in Q2 2026 and has held it in 2 quarters since. The position peaked at $15.3K in Q2 2026. 5 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

Green Ridge Wealth Planning held 10,000 shares of Actuate Therapeutics worth $7.8K as of Q3 2026.
Green Ridge Wealth Planning left its Actuate Therapeutics share count unchanged in Q3 2026.
Actuate Therapeutics made up ﹤0.01% of Green Ridge Wealth Planning's portfolio in Q3 2026, its #88 holding.
Green Ridge Wealth Planning first reported a position in Actuate Therapeutics in Q2 2026 and has held it in 2 quarters since.
Green Ridge Wealth Planning's Actuate Therapeutics position peaked at $15.3K in Q2 2026.
5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Green Ridge Wealth Planning's 13F filing for Q3 2026, filed 8 Oct 2026.